

E' indicata una terapia di mantenimento nel post-trapianto?

Presentazione del quesito

Fabio Ciceri
IRCCS H San Raffaele
Milano

CONVEGNO EDUCAZIONALE GITMO

HOT QUESTIONS IN TRASPLANTATION AND CELLULAR THERAPIES


Udine

13-14 novembre 2023

Aula Polifunzionale - Ospedale di Udine



Post transplant treatment options



Impact of treatment options on immune recovery

Immune recovery



Maintenance,
prophylaxis


pre-emptive

treatment

hematological



molecular



Immunomodulatory effect

improved outcomes in FLT3-wt patients (SORAML)


increased a/c GvHD in the sorafenib arm (SORMAIN)

ATF4 downregulation

IL-15 production by FLT3-ITDmut leukemic cells

donor CD8⁺/CD107a⁺/IFN- γ ⁺ cytotoxic T cells expansion

↑GvL



Mathew, Nat Med. 2018

**E' indicata una terapia di mantenimento
nel post-trapianto?**

- SI

- NO